A number of other analysts have also commented on RHHBY. Zacks Investment Research lowered shares of Roche from a hold rating to a sell rating in a report on Tuesday, November 28th. Berenberg Bank lowered shares of Roche from a buy rating to a hold rating in a report on Tuesday, October 24th. Citigroup lowered shares of Roche from a buy rating to a neutral rating in a report on Wednesday, October 18th. BNP Paribas lowered shares of Roche from a neutral rating to an underperform rating in a report on Tuesday, September 26th. Finally, Cowen reaffirmed a buy rating and issued a $38.00 price objective on shares of Roche in a research report on Tuesday, September 19th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the company. The company has a consensus rating of Hold and an average price target of $36.50.
Shares of Roche (RHHBY) traded up $0.18 on Thursday, reaching $31.76. 698,061 shares of the company’s stock were exchanged, compared to its average volume of 1,920,000. Roche has a 1 year low of $28.43 and a 1 year high of $36.82. The company has a current ratio of 1.29, a quick ratio of 0.92 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $219,420.00, a PE ratio of 22.06, a price-to-earnings-growth ratio of 2.28 and a beta of 0.67.
Several hedge funds have recently modified their holdings of the company. Parametric Portfolio Associates LLC raised its holdings in shares of Roche by 5.6% in the 3rd quarter. Parametric Portfolio Associates LLC now owns 3,806,074 shares of the company’s stock valued at $121,794,000 after purchasing an additional 200,394 shares during the period. Lenox Wealth Management Inc. grew its stake in Roche by 49.0% in the 3rd quarter. Lenox Wealth Management Inc. now owns 98,282 shares of the company’s stock valued at $3,145,000 after buying an additional 32,335 shares during the last quarter. Sterling Capital Management LLC grew its stake in Roche by 4.6% in the 3rd quarter. Sterling Capital Management LLC now owns 58,107 shares of the company’s stock valued at $1,856,000 after buying an additional 2,535 shares during the last quarter. Patten Group Inc. grew its stake in Roche by 12.2% in the 3rd quarter. Patten Group Inc. now owns 29,741 shares of the company’s stock valued at $847,000 after buying an additional 3,239 shares during the last quarter. Finally, Stonebridge Capital Advisors LLC acquired a new position in Roche in the 3rd quarter valued at about $221,000. 0.58% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION WARNING: This news story was first published by TrueBlueTribune and is owned by of TrueBlueTribune. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://www.truebluetribune.com/2018/01/03/roche-rhhby-receives-buy-rating-from-piper-jaffray-companies.html.
Roche Company Profile
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.